100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Salt Composition in bothYou Searched
Turbovas EZ 10/10mg Tablet 10s
Micro Labs Ltd.
₹184.7
Our Recommendation
Rovasday EZ 10/10mg Tablet 10s
3,352+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
High cholesterol
Customers also bought
More About Turbovas EZ
Benefits
In High cholesterol : Turbovas EZ 10mg/10mg Tablet effectively reduces the high cholesterol levels in your body and prevents the absorption of excess of cholesterol from the food that you eat. Lowering the amount of cholesterol reduces the chances of heart diseases and helps you remain healthier for longer. Take it regularly and make appropriate lifestyle changes (such as eating healthy and staying active) to maximize the effectiveness of this medicine. Keep taking it even if you feel well.
Side Effects
Side effects of Turbovas EZ Tablet The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you�re worried about them Common side effects of Turbovas EZNausea Muscle pain Headache Joint pain Diarrhea Upper respiratory tract infection Back pain Pain in extremity Fatigue
How to use
How to use Turbovas EZ Tablet Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Turbovas EZ 10mg/10mg Tablet can be taken it with or without food, although it's advisable to take it consistently at the same time.
How it works
How Turbovas EZ Tablet works Turbovas EZ 10mg/10mg Tablet is a combination of two medicines:.
Unsafe: Avoid consuming alcohol with Turbovas EZ 10mg/10mg Tablet as it is deemed unsafe.
Turbovas EZ 10mg/10mg Tablet is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Turbovas EZ 10mg/10mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Turbovas EZ 10mg/10mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Turbovas EZ 10mg/10mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Turbovas EZ 10mg/10mg Tablet may be needed. Doctor consultation is advised.Use of Turbovas EZ 10mg/10mg Tablet is not recommended in patients with severe kidney disease.
Turbovas EZ 10mg/10mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Turbovas EZ 10mg/10mg Tablet may be needed. Doctor consultation is advised.Use of Turbovas EZ 10mg/10mg Tablet is not recommended in patients with moderate to severe liver disease.
What if I forget to take it?
If a dose of Turbovas EZ 10mg/10mg Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
27, RACE COURSE ROAD, BANGALORE-560 001, INDIA
References
Yang YJ, Lee SH, Kim BS. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clin Ther. 2017;39 (1):107-17 (12 Apr. 2019)
Rosuvastatin calcium. Carolina, Puerto Rico: IPR Pharmaceuticals, Inc.; 2003
Ezetimibe. Kenilworth, New Jersey: Schering Corporation; 2007
Rosuvastatin calcium. Canovanas, PR: AstraZeneca Pharmaceuticals; 2003
Rosuvastatin and ezetimibe (14 Aug. 2024)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
